Table 5. KEGG categories enrichment for genes either overexpressed (A) or underexpressed (B) in STCs vs LTCs.
| A | |||||
|---|---|---|---|---|---|
| Id category | Name category | Adjusted p value | Non corr p value | Fold enrichment | # Genes |
| hsa05219 | Bladder cancer | 4.12e-02 | 3.30e-04 | 11.88 | 4 |
| hsa04115 | p53 signaling pathway | 4.12e-02 | 1.74e-04 | 9.39 | 5 |
| hsa04110 | Cell cycle | 4.12e-02 | 4.15e-04 | 6.08 | 6 |
| hsa05144 | Malaria | 7.75e-02 | 1.04e-03 | 8.81 | 4 |
| hsa05134 | Legionellosis | 1.55e-01 | 2.70e-03 | 6.81 | 4 |
| hsa05202 | Transcriptional misregulation in cancer | 1.55e-01 | 3.12e-03 | 4.12 | 6 |
| hsa04630 | Jak-STAT signaling pathway | 3.31e-01 | 7.77e-03 | 4.02 | 5 |
| hsa04512 | ECM-receptor interaction | 3.67e-01 | 9.85e-03 | 4.73 | 4 |
| hsa05214 | Glioma | 4.19e-01 | 1.41e-02 | 5.90 | 3 |
| hsa04621 | NOD-like receptor signaling pathway | 4.19e-01 | 1.41e-02 | 5.90 | 3 |
| hsa05218 | Melanoma | 4.82e-01 | 1.78e-02 | 5.40 | 3 |
| hsa04060 | Cytokine-cytokine receptor interaction | 6.17e-01 | 2.49e-02 | 2.64 | 6 |
| hsa04610 | Complement and coagulation cascades | 6.54e-01 | 2.85e-02 | 4.51 | 3 |
| hsa05132 | Salmonella infection | 6.83e-01 | 3.21e-02 | 4.31 | 3 |
| hsa04350 | TGF-beta signaling pathway | 7.13e-01 | 3.59e-02 | 4.12 | 3 |
| B | |||||
|---|---|---|---|---|---|
| Id category | Name category | Adjusted p value | Non corr p value | Fold enrichment | # Genes |
| hsa05032 | Morphine addiction | 1.15e-04 | 2.47e-07 | 7.30 | 11 |
| hsa04020 | Calcium signaling pathway | 1.34e-04 | 5.77e-07 | 5.03 | 14 |
| hsa04727 | GABAergic synapse | 2.30e-04 | 1.49e-06 | 6.92 | 10 |
| hsa04723 | Retrograde endocannabinoid signaling | 3.33e-04 | 2.88e-06 | 6.44 | 10 |
| hsa04970 | Salivary secretion | 9.57e-04 | 1.03e-05 | 6.36 | 9 |
| hsa04724 | Glutamatergic synapse | 1.38e-03 | 1.79e-05 | 5.26 | 10 |
| hsa04726 | Serotonergic synapse | 6.02e-03 | 1.03e-04 | 4.77 | 9 |
| hsa05414 | Dilated cardiomyopathy | 6.02e-03 | 1.04e-04 | 5.42 | 8 |
| hsa04080 | Neuroactive ligand-receptor interaction | 1.49e-02 | 2.89e-04 | 3.06 | 13 |
| hsa04666 | Fc gamma R-mediated phagocytosis | 3.19e-02 | 6.88e-04 | 4.69 | 7 |
| hsa04070 | Phosphatidylinositol signaling system | 5.85e-02 | 1.39e-03 | 4.87 | 6 |
| hsa04144 | Endocytosis | 6.14e-02 | 1.73e-03 | 2.81 | 11 |
| hsa04270 | Vascular smooth muscle contraction | 6.14e-02 | 1.86e-03 | 3.96 | 7 |
| hsa04725 | Cholinergic synapse | 6.14e-02 | 1.68e-03 | 4.03 | 7 |
| hsa05410 | Hypertrophic cardiomyopathy (HCM) | 7.37e-02 | 2.38e-03 | 4.38 | 6 |
| hsa05033 | Nicotine addiction | 7.58e-02 | 2.77e-03 | 6.74 | 4 |
| hsa00604 | Glycosphingolipid biosynthesis | 7.58e-02 | 2.78e-03 | 10.37 | 3 |
| hsa05214 | Glioma | 7.65e-02 | 2.97e-03 | 5.05 | 5 |
| hsa04540 | Gap junction | 9.38e-02 | 3.85e-03 | 3.98 | 6 |
| hsa04010 | MAPK signaling pathway | 9.38e-02 | 4.66e-03 | 2.48 | 11 |
| hsa04721 | Synaptic vesicle cycle | 9.38e-02 | 4.63e-03 | 4.56 | 5 |
| hsa04720 | Long-term potentiation | 9.38e-02 | 4.10e-03 | 4.69 | 5 |
| hsa04728 | Dopaminergic synapse | 9.38e-02 | 4.53e-03 | 3.38 | 7 |
| hsa05412 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 9.65e-02 | 5.21e-03 | 4.44 | 5 |
| hsa05031 | Amphetamine addiction | 9.65e-02 | 5.21e-03 | 4.44 | 5 |
| hsa04260 | Cardiac muscle contraction | 1.04e-01 | 5.83e-03 | 4.32 | 5 |
| hsa04062 | Chemokine signaling pathway | 1.63e-01 | 9.48e-03 | 2.70 | 8 |
The grey background highlights KEGG categories with an adjusted p-value < 0.05. Adjusted p-value represents the Benjamini – corrected p-value